AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26559572
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy alone (medical‐therapy group)
Trial: 26559572
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (PCI and medical therapy)
Trial: 24333824
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG); 12×90 minutes weekly sessions: psychoeducational group intervention
Trial: 18928089
Drug: Integrated traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated traditional Chinese and Western medicine (modified Jiawei Danggui Decection + 10 mg Loratadine tablet, once daily) for 4 weeks
Trial: 18928089
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western medicine (10 mg Loratadine tablet, once daily) for 4 weeks
Trial: 12580913
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with standardized extract for 4-5 years
Trial: 1595847
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine with pethidine 25 mg
Trial: 1595847
Drug: 0.1875% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1875% bupivacaine with pethidine 25 mg
Trial: 1595847
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine with pethidine 25 mg
Trial: 29728331
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg MDMA plus psychotherapy
Trial: 29728331
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg MDMA plus psychotherapy
Trial: 29728331
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg MDMA plus psychotherapy
Trial: 29728331
Drug: Open-label crossover
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label crossover with full-dose MDMA (100-125 mg) after 30 mg
Trial: 29728331
Drug: Open-label crossover
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label crossover with full-dose MDMA (100-125 mg) after 75 mg
Trial: 29728331
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups after full-dose MDMA (100-125 mg) at 12-month follow-up
Trial: 24969368
Drug: Jia‐Wei‐Xiao‐Yao‐San (JWXYS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jia‐Wei‐Xiao‐Yao‐San (JWXYS) with Cyperus rotundus L.
Trial: 24969368
Drug: Cyperus rotundus
RxNorm normalized name: CYPERUS ROTUNDUS ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyperus rotundus L. with Leonurus heterophyllus Sweet
Trial: 22131999
Drug: Grass Allergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grass Allergy Immunotherapy Tablet (AIT) with CED
Trial: 22131999
Drug: Grass Allergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grass Allergy Immunotherapy Tablet (AIT) without CED
Trial: 20855244
Drug: Shengmai capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shengmai capsule
Trial: 16275616
Drug: Desloratadine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine (5 mg/daily)
Trial: 16275616
Drug: Levocetirizine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine (5 mg/daily)
Trial: 12594141
Drug: Ropivacaine 5
RxNorm normalized name: fentanyl-ropivacaine 5 mcg/mL-0.1%-0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 5 mg ml(‐1) (with glucose 50 mg ml(‐1)), 3 ml
Trial: 12594141
Drug: Bupivacaine 5
RxNorm normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 5 mg ml(‐1) (with glucose 80 mg ml(‐1)), 3 ml
Trial: 11064438
Drug: IV administration
RxNorm normalized name: IV Administration Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration of synthetic peptide MBP82-98 (DEN(85)VVHFFKNIVTP(96)RT)
Trial: 11064438
Drug: IV saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV saline injections every 6 months for the first 2 years
Trial: 8759564
Drug: Ranitidine (Zantac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (Zantac effervescent tablets) 150 mg bd for two weeks, increased to qds for non-responders in the last two weeks.
Trial: 8759564
Drug: Ranitidine (Zantac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (Zantac effervescent tablets)
Trial: 1290245
Drug: Accupro monotherapy
RxNorm normalized name: Accupro
DrugBank: Quinapril (DB00881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Accupro monotherapy (5 mg to 40 mg daily)
Trial: 1290245
Drug: Accupro combined
RxNorm normalized name: Accupro
DrugBank: Quinapril (DB00881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Accupro combined with Diltiazem or a diuretic
Trial: 1290245
Drug: Self-recordings taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-recordings taken twice a day
Trial: 6405494
Drug: FreAmine III
RxNorm normalized name: Freamine III
DrugBank: Magnesium acetate (DB13996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FreAmine III (isonitrogenous amino acid control solution)
Trial: 28345961
Drug: SHUTi (Internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHUTi (Internet-based cognitive-behavioral treatment for insomnia)
Trial: 23110320
Drug: A(H1N1)pmd09 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A(H1N1)pmd09 vaccine co-administered with TIV
Trial: 23110320
Drug: A(H1N1)pmd09 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A(H1N1)pmd09 vaccine sequentially administered with TIV
Trial: 23110320
Drug: AS03-adjuvanted A(H1N1)pmd09
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted A(H1N1)pmd09 vaccine
Trial: 23110320
Drug: Non-adjuvanted A(H1N1)pmd09
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted A(H1N1)pmd09 vaccine
Trial: 23110320
Drug: Adjuvanted A(H1N1)pmd09
RxNorm normalized name: Haemagglutinin-strain A(H1N1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted A(H1N1)pmd09 vaccine
Trial: 17077346
Drug: Hyperinsulinemic euglycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic euglycemic clamp in insulin-resistant obese women
Trial: 15755853
Drug: Potassium citrate
RxNorm normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Potassium citrate (4.3 g or 40 mmol/d)
Trial: 15755853
Drug: Calcium citrate
RxNorm normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium citrate (800 mg or 20 mmol/d)
Trial: 15755853
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (potassium citrate and calcium citrate)
Trial: 12062733
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 mg twice daily (n = 17)
Trial: 11247166
Drug: Diet supplemented
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet supplemented with PUFA omega-3 (Eiconol) 8 g/day
Trial: 8751516
Drug: Heparin-coated cardiopulmonary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated cardiopulmonary bypass system (Duraflo II)
Trial: 1501618
Drug: Non-surgical therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical therapy (no Kasai procedure)
Trial: 2859255
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of salbutamol plus oxatomide
Trial: 26780408
Drug: Submaximal dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submaximal dose of mepivacaine 108 mg with epinephrine 54 μg (group I)
Trial: 26780408
Drug: Submaximal dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submaximal dose of mepivacaine 216 mg with epinephrine 108 μg (group II)
Trial: 18055678
Drug: 3.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 g/kg per day amino acid supplementation
Trial: 18055678
Drug: 2.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g/kg per day amino acid supplementation
Trial: 15632536
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (group F, n = 60)
Trial: 15632536
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl combined with bupivacaine infiltration (group FB, n = 60)
Trial: 10215955
Drug: Intranasal DDAVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal DDAVP (300 microg)
Trial: 7486483
Drug: Ribavirin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (600 mg twice daily for 12 months)
Trial: 2278056
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg dose of quinine, quinidine and cinchonine combination
Trial: 2278056
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg dose of quinine, quinidine and cinchonine combination
Trial: 31320735
Drug: Intravitreal dexamethasone
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal dexamethasone implant (IVD)
Trial: 21449624
Drug: Drug Renal
RxNorm normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug Renal Alert Pharmacy (DRAP) program
Trial: 18798228
Drug: Causal beliefs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Causal beliefs (psychological, biological addiction, ambiguous)
Trial: 16902049
Drug: Dexamethasone 1
RxNorm normalized name: dexamethasone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 1 mg/kg (15 mg maximum)
Trial: 16136902
Drug: Long-term domiciliary
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term domiciliary oxygen therapy (LTDOT)
Trial: 21136031
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine treatment only)
Trial: 9597374
Drug: Metformin up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin up to 2000 mg/day
Trial: 9597374
Drug: Lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 40 mg daily (control)
Trial: 7871082
Drug: lorazepam 0.026
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lorazepam 0.026 mg/kg
Trial: 3209284
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine 5 micrograms kg‐1 90 min before induction of anesthesia
Trial: 29516486
Drug: Prochlorperazine 10
RxNorm normalized name: prochlorperazine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine 10 mg + diphenhydramine 25 mg IV
Trial: 28409385
Drug: Dietary folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary folic acid 1.0 mg/kg
Trial: 28409385
Drug: Dietary folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary folic acid 2.0 mg/kg
Trial: 28409385
Drug: Dietary folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary folic acid 5.0 mg/kg
Trial: 28409385
Drug: Dietary folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary folic acid (0.0 mg/kg)
Trial: 26213796
Drug: Active comparison
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparison treatments
Trial: 23579349
Drug: HF toolkit,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HF toolkit, 2 onsite meetings, and a monthly phone call
Trial: 1642580
Drug: Fixed mini-dose
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed mini-dose warfarin (1 mg daily)
Trial: 1642580
Drug: Adjusted-dose warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose warfarin (to maintain INR of 2.0-4.0)
Trial: 6402612
Drug: Cefazolin sodium
RxNorm normalized name: Cefazolin Sodium
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin sodium (3 doses)
Trial: 20639632
Drug: L-carnitine (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (1,500 mg daily for 3 months)
Trial: 20639632
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group, 31 patients)
Trial: 18556425
Drug: SGLT‐IVTJ (subthreshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGLT‐IVTJ (subthreshold grid laser treatment combined with intravitreal triamcinolone injection)
Trial: 18556425
Drug: SGLT (subthreshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGLT (subthreshold grid laser treatment)
Trial: 17851262
Drug: S-1 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 60 mg/body/day (level 1)
Trial: 17851262
Drug: S-1 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 80 mg/body/day (recommended dose)
Trial: 17851262
Drug: S-1 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 100 mg/body/day (level 3)
Trial: 10733159
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of tetragastrin
Trial: 29098393
Drug: DEX (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX (1 μg/kg loading dose over 10 min, followed by 0.3-0.5 μg/kg/h continuous infusion)
Trial: 23946732
Drug: Oral meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral meperidine
Trial: 17433840
Drug: Add-on therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on therapy with irbesartan (300 mg/day)
Trial: 17433840
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (continuation of conventional therapy)
Trial: 9420364
Drug: Same treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same treatment without the eye movement
Trial: 3087076
Drug: Gabexate mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesilate (3 X 300 mg per day for 9 days as continuous intravenous infusion)
Trial: 24635772
Drug: 20% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% albumin and crystalloid solution
Trial: 24635772
Drug: Crystalloid solution
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid solution alone
Trial: 21518135
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of metformin
Trial: 21518135
Drug: 1700 mg
RxNorm normalized name: inulin 1700 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1700 mg of metformin
Trial: 17003660
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication (sertraline)
Trial: 17003660
Drug: Combined cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cognitive-behavioral therapy and antidepressant medication
Trial: 10952585
Drug: Quinine (Q(7))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (Q(7)) in combination with clindamycin (Q(7)C(7))
Trial: 10952585
Drug: Quinine (Q(7))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (Q(7)) in combination with tetracycline (Q(7)T(7))
Trial: 8831988
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CY) (4 g/m2) alone (group I)
Trial: 8831988
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CY) (4 g/m2) with recombinant human granulocyte‐macrophage colony stimulating factor (rhGM‐CSF) (5 micrograms/kg/day) (group II)
Trial: 8831988
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CY) (4 g/m2) with rhGM‐CSF (group II)
Trial: 24291168
Drug: LT patch
RxNorm normalized name: Trans-Ver-Sal 15% Wart Remover Adult Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LT patch (37.5 μg of ETEC LT)
Trial: 24291168
Drug: LT patch
RxNorm normalized name: Trans-Ver-Sal 15% Wart Remover Adult Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LT patch
Trial: 20865842
Drug: 3.75% imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75% imiquimod cream
Trial: 18562771
Drug: High-protein, low-calorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein, low-calorie diet with 3-g/day fish-oil supplementation
Trial: 11126693
Drug: Novel anticancer
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel anticancer agents targeting signal transduction and antiangiogenesis
Trial: 11126693
Drug: Classical cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical cytotoxic agents
Trial: 6437295
Drug: Inhaled metaproterenol
RxNorm normalized name: metaproterenol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled metaproterenol 10 minutes prior to exercise, in addition to theophylline (serum level 10-20 micrograms/ml)
Trial: 6437295
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metaproterenol and cromolyn with theophylline
Trial: 31868201
Drug: mLP formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mLP formula (1.7 g protein/100 kcal)
Trial: 31868201
Drug: CTRL formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTRL formula (2.1 g protein/100 kcal)
Trial: 21385806
Drug: Weekly administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly administration of low dose, high frequency ultrasound therapy (0.5 W/cm², 1 MHz, pulsed pattern of 1:4) for up to 12 weeks plus standard care
Trial: 21385806
Drug: Weekly administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly administration of low dose, high frequency ultrasound therapy
Trial: 9366940
Drug: Eltanolone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltanolone (0.2 mg/kg in elderly, 0.3 mg/kg in young)
Trial: 1394027
Drug: RIMA compounds
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIMA compounds (including moclobemide)
Trial: 28348152
Drug: SAL200 (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAL200 (0.1, 0.3, 1, 3, and 10 mg/kg of body weight)
Trial: 24223034
Drug: Desmopressin 0.2
RxNorm normalized name: DESMOPRESSIN 0.2MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin 0.2 mg nocte
Trial: 18714152
Drug: L-carnitine 1
RxNorm normalized name: L-Carnitine 1,000mg Oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine 1 g orally 3 times a day for 4 weeks
Trial: 17138063
Drug: Alemtuzumab induction
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab induction therapy followed by FK506 monotherapy
Trial: 17138063
Drug: Conventional immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunosuppression (FK506, mycophenolate mofetil and steroids) without any induction agent
Trial: 14633147
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) enoxaparin
Trial: 8942591
Drug: Sitting position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitting position during IT injection of dextrose-free bupivacaine 0.25% with fentanyl 0.005%
Trial: 8942591
Drug: Lateral position
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral position during IT injection of dextrose-free bupivacaine 0.25% with fentanyl 0.005%
Trial: 7043116
Drug: Concurrent feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent feedback from utilization review coordinators
Trial: 30785851
Drug: DPT‐IPV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPT‐IPV vaccine co‐administered with HRV vaccine
Trial: 30785851
Drug: DPT‐IPV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPT‐IPV vaccine staggered with HRV vaccine
Trial: 30227610
Drug: Marine n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine n-3 PUFA (2 g daily for three months)